• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质结构异质性:SARS-CoV 和 SARS-CoV-2 主要蛋白酶进行蛋白水解识别的基础假说。

Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2.

机构信息

Institute of Pharmacy and Molecular Biotechnology, Im Neuenheimer Feld 364, 69120, Heidelberg, Germany.

出版信息

Biochimie. 2021 Mar;182:177-184. doi: 10.1016/j.biochi.2021.01.010. Epub 2021 Jan 20.

DOI:10.1016/j.biochi.2021.01.010
PMID:33484784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7817518/
Abstract

The main protease (M) of SARS-CoV and SARS-CoV-2 is a key enzyme in viral replication and a promising target for the development of antiviral therapeutics. The understanding of this protein is based on a number of observations derived from earlier x-ray structures, which mostly consider substrates or ligands as the main reason behind modulation of the active site. This lead to the concept of substrate-induced subsite cooperativity as an initial attempt to explain the dual binding specificity of this enzyme in recognizing the cleavage sequences at its N- and C-termini, which are important processing steps in obtaining the mature protease. The presented hypothesis proposes that structural heterogeneity is a property of the enzyme, independent of the presence of a substrate or ligand. Indeed, the analysis of M structures of SARS-CoV and SARS-CoV-2 reveals a conformational diversity for the catalytically competent state in ligand-free structures. Variation in the binding site appears to result from flexibility at residues lining the S subpocket and segments incorporating methionine 49 and glutamine 189. The structural evidence introduces "structure-based recognition" as a new paradigm in substrate proteolysis by M. In this concept, the binding space in subpockets of the enzyme varies in a non-cooperative manner, causing distinct conformations, which recognize and process different cleavage sites, as the N- and C-termini. Insights into the recognition basis of the protease provide explanation to the ordered processing of cleavage sites. The hypothesis expands the conformational space of the enzyme and consequently opportunities for drug development and repurposing efforts.

摘要

SARS-CoV 和 SARS-CoV-2 的主要蛋白酶(M)是病毒复制的关键酶,也是开发抗病毒治疗药物的有前途的靶点。对这种蛋白质的理解是基于许多早期 X 射线结构的观察结果,这些结果主要将底物或配体作为调节活性位点的主要原因。这导致了底物诱导亚基协同性的概念,作为解释该酶双结合特异性的初始尝试,以识别其 N 和 C 末端的切割序列,这是获得成熟蛋白酶的重要加工步骤。提出的假设表明,结构异质性是酶的固有特性,与底物或配体的存在无关。事实上,对 SARS-CoV 和 SARS-CoV-2 的 M 结构的分析揭示了在无配体结构中催化活性状态的构象多样性。结合位点的变化似乎是由于 S 亚口袋中残基的灵活性以及包含甲硫氨酸 49 和谷氨酰胺 189 的片段造成的。结构证据将“基于结构的识别”引入 M 的底物蛋白水解的新范例中。在这个概念中,酶的亚口袋中的结合空间以非协同的方式变化,导致不同的构象,这些构象识别和处理不同的切割位点,就像 N 和 C 末端一样。对蛋白酶识别基础的深入了解为切割位点的有序加工提供了解释。该假设扩展了酶的构象空间,从而为药物开发和重新利用提供了机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/efa088ef93ca/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/3695ccb8e8f5/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/e95a485f0397/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/59bdd0930312/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/efa088ef93ca/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/3695ccb8e8f5/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/e95a485f0397/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/59bdd0930312/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcad/7817518/efa088ef93ca/gr3_lrg.jpg

相似文献

1
Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2.蛋白质结构异质性:SARS-CoV 和 SARS-CoV-2 主要蛋白酶进行蛋白水解识别的基础假说。
Biochimie. 2021 Mar;182:177-184. doi: 10.1016/j.biochi.2021.01.010. Epub 2021 Jan 20.
2
Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.冠状病毒主要蛋白酶与药物候选 PF-07321332 结合的结构基础。
J Virol. 2022 Apr 27;96(8):e0201321. doi: 10.1128/jvi.02013-21. Epub 2022 Apr 7.
3
SARS-CoV-2 M inhibitors and activity-based probes for patient-sample imaging.SARS-CoV-2 M 抑制剂和基于活性的探针用于患者样本成像。
Nat Chem Biol. 2021 Feb;17(2):222-228. doi: 10.1038/s41589-020-00689-z. Epub 2020 Oct 22.
4
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.SARS-CoV-2 主蛋白酶与非共价抑制剂 ML188 复合物的晶体结构
Viruses. 2021 Jan 25;13(2):174. doi: 10.3390/v13020174.
5
In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.计算机模拟研究评估新型冠状病毒(COVID-19)和 SARS-CoV 的 3C 样蛋白酶的新型结构的抗病毒活性。
Med Chem. 2021;17(4):380-395. doi: 10.2174/1573396316999200727125522.
6
Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.针对 SARS-CoV-2 主蛋白酶的肽模拟抑制剂的共价和非共价结合自由能计算。
Phys Chem Chem Phys. 2021 Mar 21;23(11):6746-6757. doi: 10.1039/d1cp00266j. Epub 2021 Mar 12.
7
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.羟乙胺类似物的抗病毒评估:针对 SARS-CoV-2 主蛋白酶(3CLpro)的抑制剂,一种虚拟筛选和模拟方法。
Bioorg Med Chem. 2021 Oct 1;47:116393. doi: 10.1016/j.bmc.2021.116393. Epub 2021 Sep 4.
8
Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.肽醛抑制剂挑战了 SARS-CoV 主蛋白酶的底物特异性。
Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11.
9
Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.基于结构的虚拟筛选发现新型 SARS-CoV-2 主蛋白酶抑制剂
J Chem Inf Model. 2020 Dec 28;60(12):5781-5793. doi: 10.1021/acs.jcim.0c00546. Epub 2020 Aug 4.
10
Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.SARS-CoV 共价非共价抑制剂与 SARS-CoV-2 木瓜蛋白酶样蛋白酶和卵巢肿瘤结构域去泛素化酶的结合。
Biomolecules. 2021 May 28;11(6):802. doi: 10.3390/biom11060802.

引用本文的文献

1
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics.从 COVID-19 中吸取的教训:应对当前和未来大流行的计算策略。
Int J Mol Sci. 2023 Feb 23;24(5):4401. doi: 10.3390/ijms24054401.
2
A new inactive conformation of SARS-CoV-2 main protease.严重急性呼吸综合征冠状病毒2型主要蛋白酶的一种新的无活性构象。
Acta Crystallogr D Struct Biol. 2022 Mar 1;78(Pt 3):363-378. doi: 10.1107/S2059798322000948. Epub 2022 Feb 21.
3
Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.

本文引用的文献

1
Mechanisms of ligand binding.配体结合机制。
Biophys Rev (Melville). 2020 Dec;1(1):011303. doi: 10.1063/5.0020997.
2
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.猫冠状病毒药物可抑制新型冠状病毒的主要蛋白酶并阻断病毒复制。
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
3
Structural plasticity of SARS-CoV-2 3CL M active site cavity revealed by room temperature X-ray crystallography.室温 X 射线晶体学揭示 SARS-CoV-2 3CL M 活性位点腔的结构可塑性。
基于二元定量构效关系指导的针对严重急性呼吸综合征冠状病毒2主要蛋白酶的FDA批准药物及临床研究中的化合物的虚拟筛选
Turk J Biol. 2021 Aug 30;45(4):459-468. doi: 10.3906/biy-2106-61. eCollection 2021.
4
Precursors of Viral Proteases as Distinct Drug Targets.病毒蛋白酶的前体作为独特的药物靶点。
Viruses. 2021 Oct 2;13(10):1981. doi: 10.3390/v13101981.
5
Inhibitor potency and assay conditions: A case study on SARS-CoV-2 main protease.抑制剂效力与测定条件:以严重急性呼吸综合征冠状病毒2主蛋白酶为例的研究
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2106095118.
6
Asymmetric dynamics of dimeric SARS-CoV-2 and SARS-CoV main proteases in an apo form: Molecular dynamics study on fluctuations of active site, catalytic dyad, and hydration water.无配体形式下二聚体SARS-CoV-2和SARS-CoV主要蛋白酶的不对称动力学:活性位点、催化二元体和水化水波动的分子动力学研究
BBA Adv. 2021;1:100016. doi: 10.1016/j.bbadva.2021.100016. Epub 2021 Jun 20.
7
Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M Inhibitor.α-红霉内酯的骨架跃迁可直接获得美国食品药品监督管理局批准的色甘酸作为一种严重急性呼吸综合征冠状病毒2 M蛋白抑制剂。
Pharmaceuticals (Basel). 2021 Jun 5;14(6):541. doi: 10.3390/ph14060541.
8
Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.橄榄来源三萜抑制 SARS-CoV-2 主要蛋白酶:有前途的未来治疗学支架。
Molecules. 2021 May 1;26(9):2654. doi: 10.3390/molecules26092654.
9
A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.与 SARS-CoV 相比,SARS-CoV-2 主蛋白酶活性位点的灵活性更高,以及针对多构象体的新型抑制剂虚拟筛选的潜力。
J Biomol Struct Dyn. 2022;40(19):9214-9234. doi: 10.1080/07391102.2021.1924271. Epub 2021 May 10.
Nat Commun. 2020 Jun 24;11(1):3202. doi: 10.1038/s41467-020-16954-7.
4
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.博赛匹韦、GC-376 和钙蛋白酶抑制剂 II、XII 通过靶向病毒主蛋白酶抑制 SARS-CoV-2 病毒复制。
Cell Res. 2020 Aug;30(8):678-692. doi: 10.1038/s41422-020-0356-z. Epub 2020 Jun 15.
5
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.靶向冠状病毒主蛋白酶的二聚化:一种有潜力的广谱治疗策略。
ACS Comb Sci. 2020 Jun 8;22(6):297-305. doi: 10.1021/acscombsci.0c00058. Epub 2020 May 27.
6
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.新型冠状病毒主蛋白酶抑制剂卡莫氟的结构基础
Nat Struct Mol Biol. 2020 Jun;27(6):529-532. doi: 10.1038/s41594-020-0440-6. Epub 2020 May 7.
7
Conformational selection in the flaviviral NS2B-NS3 protease.黄病毒 NS2B-NS3 蛋白酶的构象选择。
Biochimie. 2020 Jul;174:117-125. doi: 10.1016/j.biochi.2020.04.014. Epub 2020 Apr 23.
8
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.基于结构的针对 SARS-CoV-2 主蛋白酶的抗病毒药物候选物的设计。
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
9
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
10
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.